Clinical Trial News and Research

RSS

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia. The event marks the 50th anniversary of the discovery of the first genetic abnormality associated with cancer, and the first to lead to a targeted therapy for cancer.

25 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

Guided Therapeutics receives fund to commercialize LightTouch for cervical cancer detection

Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.

25 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

Insuring your health: Health law requires continued coverage for patients in clinical trials

In her latest Kaiser Health News consumer column, Michelle Andrews writes: "When Richard Crusoe was diagnosed with a rare form of soft tissue cancer called liposarcoma, the retired firefighter and his family pinned their hopes of slowing the cancer's advance on a drug that was being tested in a clinical trial" (Andrews, 8/24).

25 Aug 2010

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer.

25 Aug 2010

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Kamada, Ltd., a biopharmaceutical company engaged in development, production and marketing of specialty life-saving therapeutics and Baxter International Inc., a global, diversified healthcare company announced today that they have entered into an exclusive distribution and manufacturing agreement for Kamada's liquid, ready to use, intravenous Alpha-1 Antitrypsin Product for the treatment of hereditary Alpha-1 Antitrypsin Deficiency approved by the USFDA on July 1st, 2010 for marketing under the trade name "Glassia™".

From Baxter International Inc. 25 Aug 2010

Some health overhaul policies good for consumers, bad for brokers

As changes mandated by the health law continue to emerge, news outlets are exploring how the measure will alter the landscape for consumers and for insurance professionals.

25 Aug 2010

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene, LLC and the Medco Research Institute, LLC, a wholly-owned subsidiary of Medco Health Solutions, Inc., today announced that they have entered into a novel investigative research collaboration to evaluate whether variation in genetic biomarkers previously identified by SureGene can help predict drug response for widely prescribed antipsychotic drugs in patients with serious mental illness.

25 Aug 2010

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

25 Aug 2010

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza.

25 Aug 2010

BioPharm Systems enters Inc. magazine's list of fastest-growing private companies in U.S

BioPharm Systems, a leading provider of clinical trial, data, and safety solutions, today announced that it has been named to Inc. magazine's list of the fastest-growing private companies in the United States for 2010. The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period. BioPharm Systems was recognized for its 60 percent three-year growth rate.

25 Aug 2010

Echo Therapeutics completes clinical study of Prelude SkinPrep System

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude.

25 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

24 Aug 2010

First Edition: August 24, 2010

In today's headlines, a federal court judge blocks the Obama administration's stem cell policy. Meanwhile, state action related to health reform and health policy continues.

24 Aug 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

EDAP's gross profit reduces 5.1% in 2010 second quarter

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today financial results for the second quarter ended June 30, 2010. The Company outlines strategic initiatives to counter the continuing weak global economic climate.

24 Aug 2010

PEM scanners demonstrate improved specificity with high sensitivity in breast cancer diagnosis: Study

In a recent study presented at the American Association of Physicists in Medicine (AAPM) 52nd Annual Meeting, researchers at the University of Washington showed that 18FDG dose for Positron Emission Mammography (PEM) may be reduced by as much as 70% without altering image quality.

24 Aug 2010

Spaulding Clinical becomes world’s largest provider for Mortara Surveyor telemetry-monitoring capability

Spaulding Clinical Research, a Phase 1 Clinical Pharmacology Research Unit and Core ECG Lab announced today that renovation of the clinic's second floor, which was completed on Aug. 20, has made Spaulding Clinical the largest provider of Mortara Surveyor telemetry-monitoring capability in the clinical research world.

24 Aug 2010

Clinical Trial News and Research

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Guided Therapeutics receives fund to commercialize LightTouch for cervical cancer detection

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

Insuring your health: Health law requires continued coverage for patients in clinical trials

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Some health overhaul policies good for consumers, bad for brokers

SureGene collaborates with Medco Health Solutions to conduct REST study

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

BioPharm Systems enters Inc. magazine's list of fastest-growing private companies in U.S

Echo Therapeutics completes clinical study of Prelude SkinPrep System

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

First Edition: August 24, 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

EDAP's gross profit reduces 5.1% in 2010 second quarter

PEM scanners demonstrate improved specificity with high sensitivity in breast cancer diagnosis: Study

Spaulding Clinical becomes world’s largest provider for Mortara Surveyor telemetry-monitoring capability

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer